Bailard, Inc. Viracta Therapeutics, Inc. Transaction History

Bailard, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	SELL	$1.03 - $1.58 $36,875 - $56,565	-35,801 Reduced 75.05%	11,899 $12,000
Q2 2023 Jul 20, 2023	BUY	$0.89 - $2.13 $24,742 - $59,214	27,800 Added 139.7%	47,700 $67,000
Q1 2023 May 08, 2023	BUY	$1.38 - $2.29 $27,461 - $45,571	19,900 New	19,900 $31,000
Q4 2021 Feb 10, 2022	SELL	$3.37 - $7.91 $168,500 - $395,500	-50,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$7.84 - $12.53 $744,800 - $1.19 Million	-95,000 Reduced 65.52%	50,000 $401,000
Q2 2021 Aug 13, 2021	BUY	$7.55 - $12.95 $815,400 - $1.4 Million	108,000 Added 291.89%	145,000 $1.64 Million
Q1 2021 May 13, 2021	BUY	$7.58 - $18.67 $280,460 - $690,790	37,000 New	37,000 $342,000

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.